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Abstract Type II CRISPR immune systems in bacteria use a dual RNA-guided DNA endonuclease, 
Cas9, to cleave foreign DNA at specific sites. We show here that Cas9 assembles with hybrid guide 
RNAs in human cells and can induce the formation of double-strand DNA breaks (DSBs) at a site 
complementary to the guide RNA sequence in genomic DNA. This cleavage activity requires 
both Cas9 and the complementary binding of the guide RNA. Experiments using extracts from 
transfected cells show that RNA expression and/or assembly into Cas9 is the limiting factor for 
Cas9-mediated DNA cleavage. In addition, we find that extension of the RNA sequence at the 
3′ end enhances DNA targeting activity in vivo. These results show that RNA-programmed genome 
editing is a facile strategy for introducing site-specific genetic changes in human cells.
DOI: 10.7554/eLife.00471.001
Introduction
Methods for introducing site-specific double-strand DNA (dsDNA) breaks (DSBs) in genomic DNA 
have transformed our ability to engineer eukaryotic organisms by initiating DNA repair pathways that 
lead to targeted genetic re-programming. Zinc-finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) have proved effective for such genomic manipulation but their use has 
been limited by the need to engineer a specific protein for each dsDNA target site and by off-target 
activity (Urnov et al., 2010; Bogdanove and Voytas, 2011). Thus, alternative strategies for triggering 
site-specific DNA cleavage in eukaryotic cells are of great interest.
Research into genome defense mechanisms in bacteria showed that CRISPR (Clustered Regularly 
Interspaced Short Palindromic Repeats)/Cas (CRISPR-associated) loci encode RNA-guided adaptive 
immune systems that can destroy foreign DNA (Bhaya et al., 2011; Terns and Terns, 2011; Wiedenheft 
et al., 2012). The Type II CRISPR/Cas systems require a single protein, Cas9, to catalyze DNA cleavage 
(Sapranauskas et al., 2011). Cas9 generates blunt DSBs at sites defined by a 20-nucleotide guide 
sequence contained within an associated CRISPR RNA (crRNA) transcript (Gasiunas et al., 2012; 
Jinek et al., 2012). Cas9 requires both the guide crRNA and a trans-activating crRNA (tracrRNA) that 
is partially complementary to the crRNA for site-specific DNA recognition and cleavage (Deltcheva 
et al., 2011; Jinek et al., 2012). Recent experiments showed that the crRNA:tracrRNA complex can 
be redesigned as a single transcript (single-guide RNA or sgRNA) encompassing the features required 
for both Cas9 binding and DNA target siterecognition (Jinek et al., 2012). Using sgRNA, Cas9 can be 
programmed to cleave double-stranded DNA at any site defined by the guide RNA sequence and 
including a GG protospacer-adjacent (PAM) motif (Sapranauskas et al., 2011; Jinek et al., 2012). 
These findings suggested the exciting possibility that Cas9:sgRNA complexes might constitute a 
simple and versatile RNA-directed system for generating DSBs that could facilitate site-specific 
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genome editing. However, it was not known whether such a bacterial system would function in eukary-
otic cells.
We show here that Cas9 can be expressed and localized to the nucleus of human cells, and that it 
assembles with sgRNA in vivo.These complexes can generate double stranded breaks and stimulate 
non-homologous end joining (NHEJ) repair in genomic DNA at a site complementary to the sgRNA 
sequence, an activity that requires both Cas9 and the sgRNA. Extension of the RNA sequence at its 
3′ end enhances DNA targeting activity in vivo. Further, experiments using extracts from transfected 
cells show that sgRNA assembly into Cas9 is the limiting factor for Cas9-mediated DNA cleavage. 
These results demonstrate the feasibility of RNA-programmed genome editing in human cells.
Results
To test whether Cas9 could be programmed to cleave genomic DNA in vivo, we co-expressed Cas9 
together with an sgRNA designed to target the human clathrin light chain (CLTA) gene. The CLTA 
genomic locus has previously been targeted and edited using ZFNs (Doyon et al., 2011). We first 
tested the expression of a human-codon-optimized version of the Streptococcus pyogenes Cas9 
protein and sgRNA in human HEK293T cells. The 160 kDa Cas9 protein was expressed as a fusion 
protein bearing an HA epitope, a nuclear localization signal (NLS), and green fluorescent protein (GFP) 
attached to the C-terminus of Cas9 (Figure 1A). Analysis of cells transfected with a vector encoding 
the GFP-fused Cas9 revealed abundant Cas9 expression and nuclear localization (Figure 1B). Western 
blotting confirmed that the Cas9 protein is expressed largely intact in extracts from these cells 
(Figure 1A). To program Cas9, we expressed sgRNA bearing a 5′-terminal 20-nucleotide sequence 
complementary to the target DNA sequence, and a 42-nucleotide 3′-terminal stem loop structure 
required for Cas9 binding (Figure 1C). This 3′-terminal sequence corresponds to the minimal stem-
loop structure that has previously been used to program Cas9 in vitro (Jinek et al., 2012). The expres-
sion of this sgRNA was driven by the human U6 (RNA polymerase III) promoter (Medina and Joshi, 
1999). Northern blotting analysis of RNA extracted from cells transfected with the U6 promoter-driven 
sgRNA plasmid expression vector showed that the sgRNA is indeed expressed, and that their stability 
is enhanced by the presence of Cas9 (Figure 1D).
Next, we investigated whether site-specific DSBs are generated in HEK293T cells transfected 
with Cas9-HA-NLS-mCherry and the CLTA1 sgRNA. To do this, we probed for minor insertions and 
deletions in the locus resulting from imperfect repair by DSB-induced NHEJ using the Surveyor nuclease 
eLife digest The ability to make specific changes to DNA—such as changing, inserting or 
deleting sequences that encode proteins—allows researchers to engineer cells, tissues and 
organisms for therapeutic and practical applications. Until now, such genome engineering has 
required the design and production of proteins with the ability to recognize a specific DNA 
sequence. The bacterial protein, Cas9, has the potential to enable a simpler approach to genome 
engineering because it is a DNA-cleaving enzyme that can be programmed with short RNA 
molecules to recognize specific DNA sequences, thus dispensing with the need to engineer a 
new protein for each new DNA target sequence.
Now Jinek et al. demonstrate the capability of RNA-programmed Cas9 to introduce targeted 
double-strand breaks into human chromosomal DNA, thereby inducing site-specific genome editing 
reactions. Cas9 assembles with engineered single-guide RNAs in human cells and the resulting 
Cas9-RNA complex can induce the formation of double-strand breaks in genomic DNA at a site 
complementary to the guide RNA sequence. Experiments using extracts from transfected cells 
show that RNA expression and/or assembly into Cas9 is the limiting factor for the DNA cleavage, 
and that extension of the RNA sequence at the 3′ end enhances DNA targeting activity in vivo.
These results show that RNA-programmed genome editing is a straightforward strategy for 
introducing site-specific genetic changes in human cells, and the ease with which it can programmed 
means that it is likely to become competitive with existing approaches based on zinc finger nucleases 
and transcription activator-like effector nucleases, and could lead to a new generation of experiments 
in the field of genome engineering for humans and other species with complex genomes.
DOI: 10.7554/eLife.00471.002
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Figure 1. Co-expression of Cas9 and guide RNA in human cells generates double-strand DNA breaks at the target 
locus. (A) Top: schematic diagram of the Cas9-HA-NLS-GFP expression construct. Bottom: lysate from HEK293T cells 
transfected with the Cas9 expression plasmid was analyzed by Western blotting using an anti-HA antibody.  
(B) Fluorescence microscopy of HEK293T cells expressing Cas9-HA-NLS-GFP. (C) Blue line indicates the sequence used 
for the guide segment of CLTA1 sgRNA. Top: schematic diagram of the sgRNA target site in exon 7 of the human CLTA 
gene. The target sequence that hybridizes to the guide segment of CLTA1 sgRNA is indicated by the blue line. The 
GG nucleotide protospacer adjacent motif (PAM) is highlighted in yellow. Black lines denote the DNA binding regions 
Figure 1. Continued on next page
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of the control ZFN protein. The translation stop codon of the CLTA open reading frame is highlighted in red for 
reference. Middle: schematic diagram of the sgRNA expression construct. The RNA is expressed under the control of 
the U6 Pol III promoter and a poly(T) tract that serves as a Pol III transcriptional terminator signal. Bottom: sgRNA-guided 
cleavage of target DNA by Cas9. The sgRNA consists of a 20-nt 5′-terminal guide segment (blue) followed by a 42-nt 
stem-loop structure required for Cas9 binding (red). Cas9-mediated cleavage of the two target DNA strands occurs 
upon unwinding of the target DNA and formation of a duplex between the guide segment of the sgRNA and the target 
DNA. This is dependent on the presence of a GG dinucleotide PAM downstream of the target sequence in the target 
DNA. Note that the target sequence is inverted relative to the upper diagram. (D) Northern blot analysis of sgRNA 
expression in HEK239T cells. (E) Surveyor nuclease assay of genomic DNA isolated from HEK293T cells expressing Cas9 
and/or CLTA sgRNA. A ZFN construct previously used to target the CLTA locus (Doyon et al., 2011) was used as a 
positive control for detecting DSB-induced DNA repair by non-homologous end joining.
DOI: 10.7554/eLife.00471.003
The following figure supplements are available for figure 1:
Figure supplement 1. Mutated alleles of the CLTA gene in HEK293T cells as a result of Cas9-induced NHEJ.
DOI: 10.7554/eLife.00471.004
Figure 1. Continued
assay (Qiu et al., 2004). The region of genomic DNA targeted by Cas9:sgRNA is amplified by PCR and 
the resulting products are denatured and reannealed. The rehybridized PCR products are incubated 
with the mismatch recognition endonuclease Cel-1 and resolved on an acrylamide gel to identify Cel-1 
cleavage bands. As DNA repair by NHEJ is typically induced by a DSB, a positive signal in the Surveyor 
assay indicates that genomic DNA cleavage has occurred. Using this assay, we detected cleavage of the 
CLTA locus at a position targeted by the CLTA1 sgRNA (Figure 1E). A pair of ZFNs that target a neigh-
boring site in the CLTA locus provided a positive control in these experiments (Doyon et al., 2011).
To determine if either Cas9 or sgRNA expression is a limiting factor in the observed genome editing 
reactions, lysates prepared from the transfected cells were incubated with plasmid DNA harboring a frag-
ment of the CLTA gene targeted by the CLTA1 sgRNA. Plasmid DNA cleavage was not observed upon 
incubation with lysate prepared from cells transfected with the Cas9-HA-NLS-GFP expression vector alone, 
consistent with the Surveyor assay results. However, robust plasmid cleavage was detected when the lysate 
was supplemented with in vitro transcribed CLTA1 sgRNA (Figure 2A). Furthermore, lysate prepared from 
cells transfected with both Cas9 and sgRNA expression vectors supported plasmid cleavage, while lysates 
from cells transfected with the sgRNA-encoding vector alone did not (Figure 2A). These results suggest 
that a limiting factor for Cas9 function in human cells could be assembly with the sgRNA. We tested this 
possibility directly by analyzing plasmid cleavage in lysates from cells transfected as before in the presence 
and absence of added exogenous sgRNA. Notably, when exogenous sgRNA was added to lysate from 
cells transfected with both the Cas9 and sgRNA expression vectors, a substantial increase in DNA cleavage 
activity was observed (Figure 2B). This result indicates that the limiting factor for Cas9 function in HEK293T 
cells is the expression of the sgRNA or its loading into Cas9.
As a means of enhancing the Cas9:sgRNA assembly in vivo, we next tested the effect of extending the 
presumed Cas9-binding region of the guide RNA. Two new versions of the CLTA1 sgRNA were designed 
to include an additional 4 or 10 base pairs in the helix that mimics the base-pairing interactions between 
the crRNA and tracrRNA (Figure 3A). Additionally, the 3′-end of the guide RNA was extended by five 
nucleotides based on the native sequence of the S. pyogenes tracrRNA (Deltcheva et al., 2011). Vectors 
encoding these 3′ extended sgRNAs under the control of either the U6 or H1 Pol III promoters were 
transfected into cells along with the Cas9-HA-NLS-GFP expression vector and site-specific genome 
cleavage was tested using the Surveyor assay (Figure 3B). These results suggest that the 3′-extended 
sgRNAs support more efficient Cas9 function in vivo, although more quantitative comparisons will be 
necessary to confirm this conclusion.
Discussion
Besides serving as an invaluable research tool, targeted genome engineering in cells and organisms 
could potentially provide the path to revolutionary applications in human therapies, agricultural bio-
technology and microbial engineering. Methods of modifying the genome exploit endogenous DNA 
repair pathways that are initiated by the introduction of site-specific dsDNA cleavages. The results 
presented here provide a straightforward system of RNA-guided site-specific dsDNA cleavage using 
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the Cas9 protein from a Type II bacterial CRISPR system to promote genome editing in human cells. 
Our data show that a codon-optimized version of Cas9, when programmed by an appropriate sgRNA, 
successfully assembles into Cas9 targeting complexes to trigger site-specific DNA cleavage and repair 
by NHEJ. The efficiency of NHEJ-induced mutagenesis at the CLTA locus investigated here is consist-
ently in the range of 6–8%. This frequency is lower than that found for a ZFN pair that recognizes a 
nearby target sequence, but is within the range of frequencies observed more generally with ZFNs and 
TALENs (Bogdanove and Voytas, 2011). Our data suggest that sgRNA expression and/or its assem-
bly into Cas9, rather than Cas9 expression, localization or folding, presently limits Cas9 function in 
human cells. Higher efficiencies of Cas9-mediated genome targeting could be achieved by optimiza-
tion of the sgRNA construct design, its expression levels or its subcellular localization. We note that 
the sgRNAs used in this study are not thought to be 5′-capped or 3′-polyadenylated, which may have 
reduced their stability in vivo. This and other 5′ and 3′ end modifications might provide alternative 
approaches to enhancing Cas9:sgRNA assembly and activity in cells. Nonetheless, the levels of target-
ing observed in this study have been obtained with a minimal system that relies on simple base pairing 
to a guide RNA, in contrast to the ZFN and TALEN proteins, which require a new protein to be 
Figure 2. Cell lysates contain active Cas9:sgRNA and support site-specific DNA cleavage. (A) Lysates from cells 
transfected with the plasmid(s) indicated at left were incubated with plasmid DNA containing a PAM and the target 
sequence complementary to the CLTA1 sgRNA; where indicated, the reaction was supplemented with 10 pmol of 
in vitro transcribed CLTA1 sgRNA; secondary cleavage with XhoI generated fragments of ∼2230 and ∼3100 bp 
fragments indicative of Cas9-mediated cleavage. A control reaction using lysate from cells transfected with a ZFN 
expression construct shows fragments of slightly different size reflecting the offset of the ZFN target site relative to 
the CLTA1 target site. (B) Lysates from cells transfected with Cas9-HA-NLS-GFP expression plasmid and, where indicated, 
the CLTA1 sgRNA expression plasmid, were incubated with target plasmid DNA as in (A) in the absence or presence 
of in vitro-transcribed CLTA1 sgRNA.
DOI: 10.7554/eLife.00471.005
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engineered for each new cleavage site. RNA-guided genome editing would thus offer distinct advan-
tages due to the simplicity of the sgRNA design.
Our results thus provide the framework for implementing Cas9 as a facile molecular tool for diverse 
genome editing applications. Although not tested explicitly in this study, a powerful feature of this system 
is the potential to program Cas9 with multiple sgRNAs in the same cell, either to increase the efficiency of 
targeting at a single locus, or as a means of targeting several loci simultaneously. Such strategies would find 
broad application in genome-wide experiments and large-scale research efforts such as the development 
of multigenic disease models. As an inexpensive and rapid mechanism for triggering site-specific genome 
modification, the programmable Cas9:sgRNA system could potentially transform next-generation genome-
scale studies.
Figure 3. 3′ extension of sgRNA constructs enhances site-specific NHEJ-mediated mutagenesis. (A) The construct 
for CLTA1 sgRNA expression (top) was designed to generate transcripts containing the original Cas9-binding 
sequence v1.0 (Jinek et al., 2012), or sequences extended by 4 base pairs (v2.1) or 10 base pairs (v2.2). (B) Surveyor 
nuclease assay of genomic DNA isolated from HEK293T cells expressing Cas9 and/or CLTA sgRNA v1.0, v2.1 
or v2.2. A ZFN construct previously used to target the CLTA locus (Doyon et al., 2011) was used as a positive 
control for detecting DSB-induced DNA repair by non-homologous end joining.
DOI: 10.7554/eLife.00471.006
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Materials and methods
Plasmid design and construction
The sequence encoding Streptococcus pyogenes Cas9 (residues 1–1368) fused to an HA epitope (amino 
acid sequence DAYPYDVPDYASL), a nuclear localization signal (amino acid sequence PKKKRKVEDPKKKRKVD) 
was codon optimized for human expression and synthesized by GeneArt (Regensburg, Germany; DNA and 
protein sequences shown in supplementary file 1). Ligation-independent cloning (LIC) was used to insert 
this sequence into a pcDNA3.1-derived GFP and mCherry LIC vectors (vectors 6D and 6B, respectively, 
obtained from the UC Berkeley MacroLab), resulting in a Cas9-HA-NLS-GFP and Cas9-HA-NLS-mCherry 
fusions expressed under the control of the CMV promoter. Guide sgRNAs were expressed using expres-
sion vector pSilencer 2.1-U6 puro (Life Technologies, Carlsbad, CA) and pSuper (Oligoengine, Seattle, 
WA). RNA expression constructs were generated by annealing complementary oligonucleotides to form 
the RNA-coding DNA sequence and ligating the annealed DNA fragment between the BamHI and HindIII 
sites in pSilencer 2.1-U6 puro and BglII and HindIII sites in pSuper.
Cell culture conditions and DNA transfections
HEK293T cells were maintained in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) in a 37°C humidified incubator with 5% CO2. Cells were transiently transfected 
with plasmid DNA using either X-tremeGENE DNA Transfection Reagent (Roche Applied Science, 
Indianapolis, IN) or Turbofect Transfection Reagent (Thermo Scientific, Waltham, MA) with recom-
mended protocols. Briefly, HEK293T cells were transfected at 60–80% confluency in 6-well plates using 
0.5 μg of the Cas9 expression plasmid and 2.0 μg of the RNA expression plasmid. The transfection efficien-
cies were estimated to be 30–50% for Turbofect (Figures 1E and 2A,B) and 80–90% for X-tremegene 
(Figure 3B), based on the fraction of GFP-positive cells observed by fluorescence microscopy. 48 hr post 
transfection, cells were washed with phosphate buffered saline (PBS) and lysed by applying 250 μl lysis 
buffer (20 mM Hepes pH 7.5, 100 mM potassium chloride [KCl], 5 mM magnesium chloride [MgCl2], 
1 mM dithiothreitol [DTT], 5% glycerol, 0.1% Triton X-100, supplemented with Roche Protease Inhibitor 
cocktail) and then rocked for 10 min at 4°C. The resulting cell lysate was divided into aliquots for further 
analysis. Genomic DNA was isolated from 200 μl cell lysate using the DNeasy Blood and Tissue Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
Western blot analysis of Cas9 expression
HEK293T, transfected with the Cas9-HA-NLS-GFP expression plasmid, were harvested and lysed 
48 hr post transfection as above. 5 μl of lysate were electrophoresed on a 10% SDS polyacrylamide 
gel, blotter onto a PVDF membrane and probed with HRP-conjugated anti-HA antibody (1:1000 dilu-
tion in 1× PBS; Sigma, St. Louis, MO).
Surveyor assay
The Surveyor assay was performed as previously described (Qiu et al., 2004; Miller et al., 2007; Doyon 
et al., 2011). Briefly, the human clathrin light chain A (CLTA) locus was PCR amplified from 200 ng of 
genomic DNA using a high fidelity polymerase, Herculase II Fusion DNA Polymerase (Agilent 
Technologies, Santa Clara, CA) and forward primer 5′-GCAGCAGAAGAAGCCTTTGT-3′ and reverse 
primer 5′-TTCCTCCTCTCCCTCCTCTC-3′. 300 ng of the 360 bp amplicon was then denatured by heat-
ing to 95°C and slowly reannealed using a heat block to randomly rehybridize wild type and mutant DNA 
strands. Samples were then incubated with Cel-1 nuclease (Surveyor Kit; Transgenomic, Omaha, NE) for 
1 hr at 42°C. Cel-1 recognizes and cleaves DNA helices containing mismatches (wild type:mutant hybridi-
zation). Cel-1 nuclease digestion products were separated on a 10% acrylamide gel and visualized by 
staining with SYBR Safe (Life Technologies). Quantification of cleavage bands was performed using 
ImageLab software (Bio-Rad, Hercules, CA). The percent cleavage was determined by dividing the aver-
age intensity of cleavage products (160–200 bps) by the sum of the intensities of the uncleaved PCR 
product (360 bp) and the cleavage product. Mutations (indels) resulting from Cas9-induced DNA repair 
reactions were identified by Sanger sequencing of cloned amplicons. Briefly, the 360-bp PCR amplicon 
was treated with Taq DNA polymerase (NEB) and dATP to attach an ‘A’ base to the 3′ end of the DNA 
fragment. The DNA was then ligated into pGEM-T Easy vector (Promega, Madison, WI) according 
to the manufacturer’s protocol. Transformants were grown on Luria Broth agar plates containing 
100 μg/ml of ampicillin, 70 μg/ml 5-bromo-4-chloro-indolyl-β-D-galactopyranoside and 100 μM 
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isopropyl β-D-1-thiogalactopyranoside. Random white colonies were selected for Sanger sequenc-
ing (Quintara Biosciences, Albany, CA). Representative DNA sequences are shown in Figure 1—
figure supplement 1.
In vitro transcription
Guide RNA was in vitro transcribed using recombinant T7 RNA polymerase and a DNA template gen-
erated by annealing complementary synthetic oligonucleotides as previously described (Sternberg 
et al., 2012). RNAs were purified by electrophoresis on 7 M urea denaturing acrylamide gel, ethanol 
precipitated, and dissolved in DEPC-treated water.
Northern blot analysis
RNA was purified from HEK293T cells using the mirVana small-RNA isolation kit (Ambion). For each 
sample, 800 ng of RNA were separated on a 10% urea-PAGE gel after denaturation for 10 min at 
70°C in RNA loading buffer (0.5× TBE [pH 7.5], 0.5 mg/ml bromophenol blue, 0.5 mg xylene cyanol 
and 47% formamide). After electrophoresis at 10 W in 0.5× TBE buffer until the bromophenol blue 
dye reached the bottom of the gel, samples were electroblotted onto a Nytran membrane at 20 V for 
1.5 hr in 0.5× TBE. The transferred RNAs were cross-linked onto the Nytran membrane in UV-Crosslinker 
(Strategene) and were pre-hybridized at 45°C for 3 hr in a buffer containing 40% formamide, 5× SSC, 
3× Dernhardt’s solution (0.1% each of ficoll, polyvinylpyrollidone, and BSA) and 200 µg/ml Salmon 
sperm DNA. The pre-hybridized membranes were incubated overnight in the prehybridization buffer 
supplemented with 5′-32P-labeled antisense DNA oligo probe at 1 million cpm/ml. After several washes 
in SSC buffer (final wash in 0.2× SCC), the membranes were imaged phosphorimaging.
In vitro cleavage assay
Cell lysates were prepared as described above and incubated with CLTA-RFP donor plasmid (Doyon 
et al., 2011). Cleavage reactions were carried out in a total volume of 20 μl and contained 10 μl lysate, 
2 μl of 5× cleavage buffer (100 mM HEPES pH 7.5, 500 mM KCl, 25 mM MgCl2, 5 mM DTT, 25% glyc-
erol) and 300 ng plasmid. Where indicated, reactions were supplemented with 10 pmol of in vitro 
transcribed CLTA1 sgRNA. Reactions were incubated at 37°C for 1 hr and subsequently digested with 
10 U of XhoI (NEB) for an additional 30 min at 37°C. The reactions were stopped by the addition of 
Proteinase K (Thermo Scientific) and incubated at 37°C for 15 min. Cleavage products were analyzed 
by electrophoresis on a 1% agarose gel and stained with SYBR Safe. The presence of ∼2230 and ∼3100 bp 
fragments is indicative of Cas9-mediated cleavage.
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